Pfizer's tilrekimig meets primary endpoint in phase 2 eczema trial

October 1, 2026 2:30 AM

Pfizer Inc. (NYSE: PFE) presented detailed results from an ongoing Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found